Veracyte, Inc. /
Convergent Genomics Inc.
Veracyte, Inc. completed its deal for Convergent Genomics Inc.
Source for the buyer and target: Veracyte, Inc.
For the buyer and target.
“On September 10, 2026, Veracyte, Inc., a Delaware corporation (“Veracyte”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Compass Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Veracyte (“Merger Sub”), Convergent Genomics Inc., a Delaware corporation (“Convergent”), and Shareholder Representative Services LLC, as the exclusive representative of the Securityholder Indemnifying Parties (as defined in the Merger Agreement) in connection with the transactions contemplated by the Merger Agreement.”
Published 14 Sep 2026
Open the sourceWhat happened
The deal for Convergent Genomics Inc. has closed, with Veracyte, Inc. as the buyer, at a stated price of $150 million in cash. [01]
The filing from Veracyte, Inc. is dated Sept. 14, 2026. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Veracyte, Inc. completed its deal for Convergent Genomics Inc.
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly